Overview

A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
An Open-label, Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of RIST4721 in Subjects with Familial Mediterranean Fever
Phase:
Phase 2
Details
Lead Sponsor:
Aristea Therapeutics, Inc.